Flexibility is crucial to navigating geopolitical instability in clinical trials
The 2020s thus far have been fraught with unforeseen circumstances with pharmaceutical companies working through everything from a global pandemic …
Post
-
-
Obstructive sleep apnea independently associated with cerebral microbleeds
Obstructive sleep apnea (OSA) is a condition in which airflow is blocked during sleep for longer than 10 seconds at …
-
FDA unveils new pathway to usher bespoke therapies to market
The US Food and Drug Administration (FDA) has created a new pathway to bring personalised therapies to market that can …
-
Clinical Trials Arena Excellence Awards 2025: WCG
WCG, a tech-enabled partner with over 55 years’ experience accelerating clinical research while safeguarding participant safety, won the Innovation Award …
-
Novartis to seek approval of anti-malaria drug on Phase III success
Novartis’ anti-malaria drug could mark the first major advancement in more than 25 years after it showed non-inferiority in a …
-
Advarra and IgniteData team up for secure trial data transfer
Advarra and IgniteData have formed a partnership to facilitate secure transfer of clinical trial data between research sites’ Advarra’s eSource …
-
EuropaBio calls for “bold approach to investment” amid EU Biotech Act
Amid the European Commission’s (EC’s) public consultation on the EU Biotech Act, EuropaBio has called for the EU to adopt …
-
WCG unveils Data & Insights Solutions for clinical trials
WCG has introduced Data & Insights Solutions for optimising and expediting clinical study outcomes. The company aims to transform the trial …
-
What causes white space in early-stage drug development?
White space refers to unproductive gaps in drug development, when progress stalls due to scientific barriers or because of process, …
-
Neurogene reports interim outcomes in paediatric Rett syndrome trial
Neurogene has announced encouraging interim clinical data in the paediatric cohort from its ongoing Phase I/II trial of NGN-401 gene …
-
Trust remains a critical barrier to AI success in clinical trials
Artificial intelligence (AI) is becoming an increasingly important facet of the clinical trials landscape; however, trust in its ability remains …
-
Narcolepsy race heats up with Alkermes’ OX2R NT2 data but investors spooked
Alkermes’ oral, selective orexin 2 receptor (OX2R) agonist has met its dual primary endpoints in the high doses in a …
-
FDA’s revolving door reveals Pazdur as new CDER head
The US Food and Drug Administration (FDA) has a new chief drug regulator, with industry veteran Dr Richard Pazdur taking …
-
Sophia Genetics and Element partner to advance precision medicine research
Sophia Genetics and Element Biosciences have teamed up to advance genomic sequencing and workflows for precision medicine. Announced during the Association …
-
UK invests £60m to phase out animal testing in preclinical trials
The UK Government is investing £60m ($78.76m) to push pharma and biotech to use alternative preclinical models in a pull …
